Skip to main content
. 2018 Sep 24;62(10):e01064-18. doi: 10.1128/AAC.01064-18

TABLE 1.

Phenotypic analysis results for patients who experienced virologic breakthrough at week 96 while adherent to the study drug

Parameter TAF TDF
No. of patients phenotyped (% of patients sequenced) 18 (19) 7 (15)
    Virologic breakthrough without nonadherence 13 7
    Conserved site changes 5 0
Mean EC50 fold change from baseline 1.03 0.94
Range of fold change from baseline 0.39–1.51 0.63–1.69